The US FDA Approves Patient Specific Talus Spacer to Treat AVN of Ankle Joint as a Humanitarian Use Device

 The US FDA Approves Patient Specific Talus Spacer to Treat AVN of Ankle Joint as a Humanitarian Use Device

The US FDA Approves Patient Specific Talus Spacer to Treat AVN of Ankle Joint as a Humanitarian Use Device

Shots:

  • The FDA has approved Patient-Specific Talus Spacer 3D-printed talus implant for humanitarian use. The FDA reviewed data through the HDE process
  • Data supporting the safety of implant include results from 31 patients and 32 talus replacement surgeries with the implant. Post-operation @3yrs, pain decreased from “mod. to sev.” prior to surgery to “mild” post-surgery, and range of motion in the ankle joint is also improved
  • The implant is the first of its kind to replace the talus for the treatment of AVN of ankle joint. The implant provides a joint-sparing alternative to other surgical interventions used in late-stage AVN that may disable motion of the ankle joint

Click here ­to­ read full press release/ article | Ref:  FDA | Image: Crunchbase

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post